# reload+after+2024-01-21 18:47:32.865758
address1§1751 River Run
address2§Suite 400
city§Fort Worth
state§TX
zip§76107
country§United States
phone§817 438 6168
website§https://tffpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas.
fullTimeEmployees§15
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Harlan F. Weisman', 'age': 71, 'title': 'President, CEO & Director', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 594479, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kirk Allen Coleman', 'age': 49, 'title': 'CFO, Treasurer & Secretary', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 382220, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Zamaneh  Mikhak M.D.', 'age': 59, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.264
priceToSalesTrailing12Months§15.1714945
currency§USD
dateShortInterest§1702598400
forwardEps§-3.64
exchange§NCM
quoteType§EQUITY
shortName§TFF Pharmaceuticals, Inc.
longName§TFF Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1572010200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9ab96840-cea4-3457-a6b0-b63404eb0e30
gmtOffSetMilliseconds§-18000000
targetHighPrice§56.0
targetLowPrice§25.0
targetMeanPrice§40.5
targetMedianPrice§40.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§8.833
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
